Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...

Learn a morning routine for psoriasis that can help relieve your symptoms like itching and pain. A dermatologist offers their top tips. If you have psoriasis, it sometimes feels like you’d do anything ...

For the 7.5 million Americans diagnosed with psoriasis, it can be disheartening to hear that there's no cure. But there are several treatments that can help keep this autoimmune disease under control.

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

January's approval by the Food and Drug Administration (FDA) of Amevive, the first biologic treatment for chronic plaque psoriasis, is a qualified blessing for the estimated 1.5 million Americans who ...